The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients
HIV Infections, Lipodystrophy
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring HIV, immune stimulation, lipodystrophy, growth hormone, recombinant growth hormone, Treatment Experienced
Eligibility Criteria
Inclusion Criteria: Male Caucasian race Age >21 years, <60 years HIV-1 infection HAART treated > 12 months HIV-RNA < 100 copies/ml CD4 count > 200 Fasting plasma glucose < 6.1 mM Stable weight Exclusion Criteria: BMI > 28 kg/m2 and BMI < 18.5 kg/m2 Wasting or AIDS defining disease Severe chronic diseases other than HIV Cancer, previous transplantation Previous AMI Diabetes Hormonal substitution therapy Lipid lowering or antidiabetic therapy within 3 months Abuse of narcotics or alcohol Major psychiatric disorders Adverse reactions towards Genotropin Calcium-ion < 1.15 or > 1.35 mM D-vitamin < 19 nM TSH < 0.1 or > 10 mIU/l
Sites / Locations
- Clinical Research Unit, Hvidovre University Hospital
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Active Comparator
1
2